Multi-Armed Anti-CD40-Mediated Dual Drug Delivery System Based on Mesoporous Silica/Au Nanorod Nanocomposites for Multimodality Imaging and Combination Therapy
Source abstract
Abstract
Nanotechnology provides the platform to develop functional nanocomposites with outstanding features, such as persistent luminescence (PL), photothermal conversion, magnetic resonance (MR), and so on, that has been incorporated in nanomedicine for diagnosis and therapy. Herein, the nanocomposites of ZnGa 2 O 4:Cr 3+ embedded in mesoporous silica coating surrounding gold nanorods (cGNR@MSNs) were developed for the codelivery of chemotherapeutic drugs and anti-CD40 antibodies. The nanocomposites were functionalized with tetrazaheterocycle linking divinylpyrimidine derivatives (DOTVs), which covalently capture anti-CD40 by disulfide re-bridging on the surface of cGNR@MSNs. The anti-CD40-mediated dual drug delivery system simultaneously realized the combination of chemo-, immuno-, and photothermal therapies, enhancing the synergistic effect of combination therapy for multiple tumor cells. Moreover, the nanodrug delivery system achieved multimodality imaging with fluorescence, PL, and MR modes for precise diagnosis. This study provides fascinating insights into the development of nanocomposite-based multimodality imaging strategies and imaging-guided combination therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Jiangsu University, Zhenjiang 212013, P. R. China
Department of Immunology, Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang 212013, P. R. China
Funding
National Natural Science Foundation of China · Senior Talent Foundation of Jiangsu University · Postgraduate Research and Practice Innovation Program of Jiangsu Province
References (69)
Show source-provided references
1. 10.1039/c4sc01195c10.1039/c4sc01195c ↗
2. 10.1039/c9cc04260a10.1039/c9cc04260a ↗
3. 10.1002/anie.20210149210.1002/anie.202101492 ↗
4. 10.1021/jacs.1c1148010.1021/jacs.1c11480 ↗
5. 10.1073/pnas.170194411410.1073/pnas.1701944114 ↗
6. 10.1038/s41598-022-21762-810.1038/s41598-022-21762-8 ↗
7. 10.1021/jacs.0c0686610.1021/jacs.0c06866 ↗
8. 10.1021/jacs.9b0193110.1021/jacs.9b01931 ↗
9. 10.1021/jacs.0c0509310.1021/jacs.0c05093 ↗
10. 10.1038/s41563-022-01384-110.1038/s41563-022-01384-1 ↗
11. 10.1002/smll.20200080910.1002/smll.202000809 ↗
12. 10.1002/adma.20170532810.1002/adma.201705328 ↗
13. 10.1038/s41557-020-0426-310.1038/s41557-020-0426-3 ↗
14. 10.1021/acsnano.1c0058510.1021/acsnano.1c00585 ↗
15. 10.1021/acsami.0c1792310.1021/acsami.0c17923 ↗
16. 10.1039/d0cs01061h10.1039/d0cs01061h ↗
17. 10.1021/jacs.8b0509310.1021/jacs.8b05093 ↗
18. 10.1002/adfm.20210022710.1002/adfm.202100227 ↗
19. 10.1016/j.jare.2022.02.01410.1016/j.jare.2022.02.014 ↗
20. 10.1016/j.jpha.2022.12.00110.1016/j.jpha.2022.12.001 ↗
21. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
22. 10.1039/d0sc06557a10.1039/d0sc06557a ↗
23. 10.1038/s41587-019-0262-410.1038/s41587-019-0262-4 ↗
24. 10.1126/sciadv.abn388310.1126/sciadv.abn3883 ↗
25. 10.1021/ja510519u10.1021/ja510519u ↗
26. 10.1126/science.abc911310.1126/science.abc9113 ↗
27. 10.1038/s41467-020-19192-z10.1038/s41467-020-19192-z ↗
28. 10.1038/s41467-020-18570-x10.1038/s41467-020-18570-x ↗
29. 10.1073/pnas.191897111710.1073/pnas.1918971117 ↗
30. 10.1111/j.1600-065x.2009.00782.x10.1111/j.1600-065x.2009.00782.x ↗
31. 10.1038/sj.cgt.770052710.1038/sj.cgt.7700527 ↗
32. 10.1038/nrc205110.1038/nrc2051 ↗
33. 10.1158/1078-0432.ccr-06-189310.1158/1078-0432.ccr-06-1893 ↗
34. 10.1038/s41467-021-23909-z10.1038/s41467-021-23909-z ↗
35. 10.1038/s41598-019-57293-y10.1038/s41598-019-57293-y ↗
36. 10.1038/842610.1038/8426 ↗
37. 10.1038/s41467-021-24347-710.1038/s41467-021-24347-7 ↗
38. 10.1038/s41423-021-00734-410.1038/s41423-021-00734-4 ↗
39. 10.3390/cancers1306130210.3390/cancers13061302 ↗
40. 10.1002/advs.20150000110.1002/advs.201500001 ↗
41. 10.1021/acsnano.0c0565510.1021/acsnano.0c05655 ↗
42. 10.1039/c7nr01488k10.1039/c7nr01488k ↗
43. 10.1016/j.biomaterials.2018.01.03110.1016/j.biomaterials.2018.01.031 ↗
44. 10.7150/thno.1658910.7150/thno.16589 ↗
45. 10.1186/s12951-021-00862-z10.1186/s12951-021-00862-z ↗
46. 10.1021/acsnano.7b0150510.1021/acsnano.7b01505 ↗
47. 10.1038/nrc323710.1038/nrc3237 ↗
48. 10.1039/c8sc04645j10.1039/c8sc04645j ↗
49. 10.1039/d1cc06766d10.1039/d1cc06766d ↗
50. 10.1039/d2cc02515a10.1039/d2cc02515a ↗
51. 10.1021/jacs.2c0969210.1021/jacs.2c09692 ↗
52. 10.1021/acs.inorgchem.0c0218910.1021/acs.inorgchem.0c02189 ↗
53. 10.1038/srep1565610.1038/srep15656 ↗
54. 10.1039/c6sc00342g10.1039/c6sc00342g ↗
55. 10.1021/cr900353810.1021/cr9003538 ↗
56. 10.1038/s41467-019-13374-010.1038/s41467-019-13374-0 ↗
57. 10.1002/ange.20220261410.1002/ange.202202614 ↗
58. 10.1038/nrc.2017.1710.1038/nrc.2017.17 ↗
59. 10.1038/nrclinonc.2016.2510.1038/nrclinonc.2016.25 ↗
60. 10.1021/nl304478h10.1021/nl304478h ↗
61. 10.1021/jacs.9b0206110.1021/jacs.9b02061 ↗
62. 10.1021/acs.biomac.1c0011810.1021/acs.biomac.1c00118 ↗
63. 10.1021/jo00060a00510.1021/jo00060a005 ↗
64. 10.1021/acs.orglett.9b0337710.1021/acs.orglett.9b03377 ↗
65. 10.1002/chem.20090266010.1002/chem.200902660 ↗
66. 10.3892/or.2011.117810.3892/or.2011.1178 ↗
67. Tong A. W. · Clin. Cancer Res. · 2001 · 7 · 691
68. 10.1021/ja052337c10.1021/ja052337c ↗
69. 10.1021/acsami.7b1221610.1021/acsami.7b12216 ↗